Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study

[1]  D. Olive,et al.  High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. , 1991, Blood.

[2]  D. Olive,et al.  Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. , 1991, European Cytokine Network.

[3]  D. Olive,et al.  Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. , 1990, Blood.

[4]  J. Reiffers,et al.  Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial , 1989, British journal of haematology.

[5]  H. Heslop,et al.  Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.

[6]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[7]  R. Gale,et al.  HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKAEMIA? , 1984, The Lancet.

[8]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[9]  S. Agarwal,et al.  Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.

[10]  J. Rossi,et al.  Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. , 1990, Bone marrow transplantation.

[11]  D. Olive,et al.  T-Cell Functional Evaluation Following Bone Marrow Transplantation , 1985 .

[12]  R. Brereton.  Letter: Treatment of spina bifida. , 1975, Lancet.